(Q24245614)

https://api.crossref.org/works/10.1002%2F14651858.CD003428.PUB2

Effectiveness and tolerability of high-dose salmeterol in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003428.PUB2

A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003428.PUB2

Effects of salmeterol on arterial oxyhemoglobin saturations in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003428.PUB2

Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003428.PUB2

Effect of Theophylline on Lung Function Tests, Sleep Quality, and Nighttime SaO2in Children with Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003428.PUB2

Response to aerosol salbutamol, SCH 1000, and placebo in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003428.PUB2

Does wearing a noseclip during inhalation improve lung deposition?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003428.PUB2

Effect of nebulized albuterol on blood glucose in patients with diabetes mellitus with and without cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003428.PUB2

Immediate effect of various treatments on lung function in infants with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003428.PUB2

Reduced effect of inhaled beta 2-adrenergic agonists on lung mucociliary clearance in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003428.PUB2

A double-blind, randomized study of sodium cromoglycate versus placebo in patients with cystic fibrosis and bronchial hyperreactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003428.PUB2

"CF asthma": what is it and what do we do about it?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003428.PUB2

British Guideline on the Management of Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003428.PUB2

Effectiveness of bronchodilators in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003428.PUB2

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003428.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003428.PUB2

Variability of airways hyper-reactivity and allergy in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003428.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003428.PUB2

Mechanisms of bronchial hyperreactivity in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003428.PUB2

7 January 2021

Efficacy of salbutamol and ipratropium bromide in decreasing bronchial hyperreactivity in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003428.PUB2

7 January 2021

Comparison of efficacy of salbutamol and sodium cromoglycate in the prevention of ticarcillin-induced bronchoconstriction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003428.PUB2

7 January 2021

Short-term and long-term effects of albuterol aerosol therapy in cystic fibrosis: a preliminary report

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003428.PUB2

7 January 2021

Patterns of medical practice in cystic fibrosis: part II. Use of therapies. Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003428.PUB2

7 January 2021

Bronchial constriction after nebulized tobramycin preparations and saline in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003428.PUB2

7 January 2021

[Role of anticholinergic agents in the treatment of cystic fibrosis]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003428.PUB2

7 January 2021

Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003428.PUB2

7 January 2021

Effect of fluticasone propionate and salmeterol on Pseudomonas aeruginosa infection of the respiratory mucosa in vitro

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003428.PUB2

7 January 2021

Effect of oral digoxin, topical ouabain and salbutamol on transepithelial nasal potential difference in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003428.PUB2

7 January 2021

Bronchial drainage with aerosol medications in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003428.PUB2

7 January 2021

The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003428.PUB2

7 January 2021

Bronchodilators increase airway instability in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003428.PUB2

7 January 2021

Effect of salmeterol on Haemophilus influenzae infection of respiratory mucosa in vitro

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003428.PUB2

7 January 2021

Effect of albuterol on maximal exercise capacity in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003428.PUB2

7 January 2021

The effect of high doses of inhaled salbutamol and ipratropium bromide in patients with stable cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003428.PUB2

7 January 2021

The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003428.PUB2

7 January 2021

A controlled trial of long-term bronchodilator therapy in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003428.PUB2

7 January 2021

Standardisation of spirometry

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD003428.PUB2

Effects of standard and high doses of salmeterol on lung function of hospitalized patients with cystic fibrosis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD003428.PUB2

Identifiers

DOI

10.1002/14651858.CD003428.PUB2

1 reference

Consolidated OpenCitations Corpus – April 2017

455130

455130

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference